Source comparison
MOTS-c for Mitochondrial Optimization: Research Comparison
MOTS-c AMPK activation, nuclear gene regulation Glucose uptake independent of insulin, fatty acid oxidation 30% improved insulin sensitivity in HFD models (Cell Metabolism 2015) SC/IM injection, intranasal First-line mitochondrial optimization tool. Dual cytop
This comparison does not assign a generated winner or score.
- MOTS-c
- AMPK activation, nuclear gene regulation
- Glucose uptake independent of insulin, fatty acid oxidation
- 30% improved insulin sensitivity in HFD models (Cell Metabolism 2015)
- SC/IM injection, intranasal
- First-line mitochondrial optimization tool. Dual cytoplasmic and nuclear action
- Humanin
- Cytoprotection via BAX inhibition
- Apoptosis prevention, neuroprotection
- Reduced beta-amyloid toxicity in AD models
- SC/IM injection
- Complementary for neuroprotective protocols, less direct metabolic impact
- SS-31 (Elamipretide)
- Cardiolipin stabilization
- Mitochondrial membrane integrity
- Improved cardiac function in heart failure trials
- IV infusion
- Clinical-stage compound, limited research availability
- NAD+ Precursors
- Sirtuins activation, mitochondrial NAD+ repletion
- Enhanced mitochondrial respiration
- Variable. 10–40% NAD+ increase depending on compound
- Oral, sublingual
- Supportive. Addresses cofactor depletion but doesn't recalibrate signaling
- Metformin
- AMPK activation via Complex I inhibition
- Reduced hepatic glucose output
- 25–30% diabetes risk reduction (DPP trial)
- Oral
- Pharmaceutical comparator. Effective but systemic side effects